DBV Technologies closes $25.5 (€19.4) million Series ‘C’ financing round including new investors InnoBio, Lundbeckfond Ventures, Shire plc, and ALTO Invest; as well as existing investors Sofinnova Partners and ALK Abello

Proceeds will be used, for the most part, to further continue the clinical development of VIASKIN® Peanut, the world’s first epicutaneous skin patch for desensitization of peanut allergy

“There are no safe treatments available for peanut allergy patients. VIASKIN® will give them the hope of living a normal life. VIASKIN® technology offers a whole new paradigm for the treatment of food allergies.” — Pierre-Henri Benhamou, M.D., CEO.

PARIS, Jan. 5, 2011—DBV Technologies, an emerging biotechnology company, announced today that it has secured $25.5 million (€19.4 million) in a Series C financing round. The round was co-led by new investors InnoBio Fund (managed by CDC Entreprises within FSI France Investment program) and Lundbeckfond Ventures. Shire plc and ALTO invest joined the round together with existing investors Sofinnova Partners and ALK Abello. Aelios Finance advised DBV Technologies on this financing transaction. Total investment in DBV Technologies also includes other investors Apax Partners, Cap Décisif, and Creagro.

DBV Technologies is the only company in the world whose products are designed to epicutaneously (via a skin patch) deliver allergens for Epicutaneous Immunotherapy (EPIIT) against food allergies such as peanut and milk. Allergen-specific immunotherapy is the only strategy that treats the underlying cause of an allergic disorder. DBV’s proprietary epicutaneous patch technology — VIASKIN® — involves maintaining an allergen on the intact skin of an allergic subject for repeated and prolonged periods in order to obtain clinical desensitization to the targeted allergen.

DBV Technologies is making its revolutionary treatment a convenient therapy compatible with pharmaceutical standards. It is worth noting that three new investors are specialized funds with strong ties to leading global pharmaceutical companies; Innobio is a fund managed by CDC Entreprises and sponsored by the French state sovereign fund FSI and leading pharmaceutical companies (Sanofi Aventis, GSK, Roche, Novartis, Pfizer, Lilly, Ipsen, Takeda and Boehringer-Ingelheim); Lundbeckfond Ventures is the Lundbeck Foundation's life science investment entity under Lundbeckfond Invest (owning 70% of the shares of Lundbeck A/S); Shire is a leading global specialty biopharmaceutical company.

“We are extremely pleased to welcome our new investors—InnoBio, Lundbeckfond Ventures, Shire plc and ALTO Invest—and we also are very happy that Sofinnova and ALK have invested in us once again,” said Pierre-Henri Benhamou, M.D., co-founder and CEO of DBV Technologies. “Since there are no known treatments for food allergies, many children and their families live with the constant fear of ingesting a life-threatening food. VIASKIN is designed to trigger the desired immune response while avoiding the risk of a systemic, life-threatening reaction. The Series C cash infusion will enable us to move forward with this life-saving technology.”

According to the Food Allergy & Anaphylaxis Network (FAAN), there are 12 million food-allergic people in the U.S., and the incidence of peanut allergy has doubled over the past five years in children.

About VIASKIN® Technology
When the VIASKIN patch containing a specific allergen is applied to the skin of a patient with an IgE-mediated allergy — such as peanuts or milk — the allergens are deposited locally on the skin and are captured specifically by the skin’s immuno-competent cells. This triggers the modulations of the immune responses. The epicutaneous exposure is non-invasive: the skin naturally prevents the allergen from entering the bloodstream and thereby dramatically reduces the
risk of inducing anaphylaxis. The VIASKIN patch is designed to be easily and painlessly applied by healthcare professionals and also by the patient or his/her parents at home, which facilitates compliance with the treatment.

**About VIASKIN® Peanut Immunotherapy**
A phase 1b clinical study of VIASKIN Peanut is underway at five centers in the U.S. — Duke University Medical Center, National Jewish Medical Research Center, Arkansas Children’s Hospital, CR1 Worldwide, and Aspen Clinical Research. VIASKIN Peanut’s development is also supported by the NIH-funded Consortium of Food Allergy Research (CoFAR) and other opinion leaders in allergy in the United States.

**About DBV Technologies**
DBV Technologies is the only company in the world whose products are designed to *epicutaneously* deliver on intact skin — via an epicutaneous patch — allergens for Epicutaneous Immunotherapy (EPIT) against food allergies. Allergen-specific immunotherapy is the *only* strategy that treats the underlying cause of an allergic disorder. DBV’s proprietary epicutaneous patch technology — VIASKIN® — involves maintaining an allergen on the skin of an allergic subject for repeated and prolonged periods in order to obtain clinical desensitization.

**NOTE:** VIASKIN® *Peanut* is only for investigational use at the moment in the USA and in Europe.

**About CDC Entreprises and Innobio**
CDC Entreprises is a management company authorized by France’s financial market regulator, the AMF, and a wholly-owned subsidiary of the Caisse des Dépôts. CDC Entreprises manages the group’s public interest activities, including the FSI (the French Strategic Fund), in the field of private equity for SMEs and other public and private institutions investing in small- and medium-size French businesses. It makes direct and indirect investments in companies, on a national or regional level, ranging from technology seed funding to small company transmissions. CDC Entreprises covers SMEs’ entire financing chain. It takes more risk than the traditional players, positioning itself much more strongly in activities such as the provision of seed money and venture capital, and targeted areas such as biotechnology. It takes stakes in SMEs’ capital up to a maximum of €15 million for any one company.

Innobio is a French venture capital fund of €139 million, managed by CDC Entreprises and for 37 per cent subscribed by the FSI and leading international pharmaceutical companies established in France such as Sanofi-Aventis, GSK, Roche, Novartis, Pfizer, Lilly, Ipsen, Takeda and Boehringer Ingelheim. The main purpose of the fund is to make direct equity and quasi-equity investments in companies that provide innovative technology products and services in the healthcare market. Innobio’s investor team, specialized in this sector and headed by Laurent Arthaud, made six investments since his launch in January 2010. www.cdcentreprises.fr

**About Lundbeckfond Ventures**
Lundbeckfond Ventures is an evergreen life science venture fund investing in companies primarily in Europe, but selectively also in the US through its network. It invests in later stage drug discovery and development, as well as in medtech and diagnostics. Lundbeckfond Ventures is part of Lundbeckfond Invest, the asset management subsidiary of the Lundbeck Foundation. Through Lundbeckfond Invest, the Lundbeck Foundation holds majority ownerships in H. Lundbeck A/S and ALK-Abelló A/S and a significant ownership in Falck A/S. www.lundbeckfonden.dk

**About Shire plc**
Shire plc is one of the world’s leading specialty biopharmaceutical companies. Shire is fully focused on a single purpose: to enable people with life-altering conditions to lead better lives. Shire has a broad portfolio and a global sales and marketing infrastructure, with operations in 28 countries around the world. Its products are also available through distributors and alliances and some are marketed in 50 or more countries worldwide.

**About ALTO INVEST**
ALTO INVEST is a capital management company investing primarily in small- and mid-sized fast-growing companies. ALTO INVEST’s team is highly experienced in managing private equity portfolios on behalf of institutional and private clients, and it has made more than 90 private equity investments in Europe. ALTO INVEST is fully approved by the French financial authorities (Autorité des Marchés Financiers) and is an active member of the French Asset Management Association (Association Française de la Gestion Financière). Investment contacts: Antoine Valdes / Benoît THIEDEY.

**About Sofinnova Partners**
Sofinnova Partners is an independent venture capital firm based in Paris, France. For over 35 years, the firm has backed nearly 500 companies at different stages of development: pure creations, spin-offs, as well as turnaround situations, and it has worked alongside Europe’s key entrepreneurs in the technology, life sciences and cleantech sectors. With €1.1 billion of funds under management, Sofinnova Partners’ experienced team and hands-on approach in building portfolio companies through to exit have created market leaders, from landmark historical investments including Genentech, Actelion and Vistaprint to more recent successes such as CoreValve, Novexel, Fovea, Sensitive Object, Movets and PreGlem. With a global mindset, the firm has a sister organization in San Francisco, California. Please visit www.sofinnova.fr for more information on Sofinnova’s team and portfolio.

**About ALK**
ALK is a research-driven global pharmaceutical company focusing on allergy treatment, prevention and diagnosis. ALK is the world leader in allergy vaccination (immunotherapy). The company has 1,700 employees with subsidiaries, production facilities and distributors worldwide. ALK is also part of a strategic partnership with Merck on tablet-based allergy vaccination in North America. The company is headquartered in Hørsholm, Denmark, and is listed on NASDAQ OMX Copenhagen A/S. Read more at www.alk-abello.com.